Frederick National Laboratory for Cancer Research

46 articles about Frederick National Laboratory for Cancer Research

• 

  The Top 12 Biopharma Companies Hiring Now

  5/1/2023

  In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
• 

  Trial Automation, Education Lapse Consequences of COVID-19 for Cancer Research

  6/16/2022

  Frederick National Laboratories, the American Cancer Society and other leaders are picking up the pieces - both good and bad - as COVID-19 becomes endemic.

• Nanotechnology Characterization Laboratory Supports Long-Term Study Evaluating Toxicity from Nanoparticles

  8/3/2020

  The Frederick National Laboratory’s Nanotechnology Characterization Laboratory recently supported a first-of-its-kind study examining whether nanoparticles used for drug delivery, vaccines, and biomedical imaging were toxic over an extended period of time. 

• Analysis of Rapid Autopsy Tumor Tissue May Offer Guidance to Stop or Slow Cancer’s Spread

  7/28/2020

  Results from genomic testing of a cancer patient’s biopsy tissue can help guide treatment decisions, depending on the types of gene mutations found. But as it spreads or stops responding to treatment, the cancer changes and develops new mutations. Insights gained from the biopsy of the primary tumor may no longer be relevant in determining next steps. 

• Compound Derived From Red Algae May Protect Against Nipah Virus

  7/15/2020

  A “Swiss army knife” protein that is active against several viruses may also offer some protection against Nipah virus, a lethal pathogen with no cure or vaccine. 

• FHI Clinical Inc. Providing Clinical Operations Services for ACTT-1 Trial of Remdesivir for Treatment of COVID-19

  7/14/2020

  FHI Clinical Inc. contracted by Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide operational support for NIAID-funded study DURHAM, N.C.--( BUSINESS WIRE )-- FHI Clinical Inc. announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptiv

• Studies Show HLA-B Gene Match with Recipient and Donor May Lead to More Successful Bone Marrow Transplant

  7/2/2020

  For patients with blood cancer such as leukemia, a bone marrow transplant can extend life or even potentially cure the disease. The ideal bone marrow donor is a close relative, such as a brother or sister. If none is available, doctors look for an unrelated donor whose stem cells best match those of the recipient.  

• Argonne-FNL Collaboration Aims to Find a SARS-CoV-2 Inhibitor

  7/2/2020

  A unique library of small-molecule fragments designed and developed by the National Cancer Institute’s RAS Initiative at the Frederick National Laboratory is now furthering the search for a COVID-19 treatment. 

• New Technical Service Supports Tuberculosis Research

  7/1/2020

  The Frederick National Laboratory for Cancer Research has initiated a new technical service offering, to support tuberculosis vaccine research efforts in nonhuman primate (NHP) model studies.  

• Frederick National Laboratory scientists optimize SARS-CoV-2 protein production to meet growing need for serology testing

  6/25/2020

  Scientists at the Frederick National Laboratory for Cancer Research (FNL) successfully increased the yield production of a challenging protein used in antibody tests for SARS-CoV-2, the virus behind COVID-19, publishing their findings earlier this month in Protein Expression and Purification. 

• Scientific partnership including Frederick National Laboratory develops highly specific test to detect antibodies to COVID-19

  6/17/2020

  Scientists at the Frederick National Laboratory for Cancer Research and investigators across the National Institutes of Health (NIH) have developed a highly specific serology test to determine whether a person has antibodies to SARS-CoV-2, a vital tool to understanding the spread of infection from the virus that causes COVID-19. 

• Study shows HPV35 infection more prevalent in African American women than other groups

  6/15/2020

  A type of the human papillomavirus (HPV) that is relatively uncommon among all women is more prevalent among women of African ancestry in the United States according to a National Cancer Institute study published in the International Journal of Cancer and co-authored by scientists at the Frederick National Laboratory for Cancer Research.  

• Analyzing tumors of cancer patients with robust response to treatment may offer clues on how others can benefit and improve tailored treatment

  6/8/2020

  Patients who have a better-than-average response to cancer treatment can help further research that might benefit all cancer patients. Analysis of their tumor tissues can provide clues about the genetic keys that make their tumor more responsive to treatment.  

• Malian Prime Minister visits CMRPD-supported University Clinical Research Center pivoting to COVID-19 research

  6/5/2020

  As word of the SARS-CoV-2 outbreak spread around the world, countries began looking inward to prepare. In Mali, Prime Minister Dr. Boubou Cisse visited University Clinical Research Center (UCRC) laboratories at the University of Sciences, Techniques, and Technologies of Bamako (USTTB) in March to see how its facilities could help.  

• New England Journal of Medicine paper shows remdesivir speeds recovery for Hospitalized COVID-19 patients

  6/4/2020

  The antiviral treatment remdesivir accelerated recovery time among hospitalized participants with advanced COVID-19 compared to participants who received placebo containing inactive ingredients, according to results of a clinical trial published May 22 in the New England Journal of Medicine.  

• Collaboration with the London School of Hygiene & Tropical Medicine investigates a single-dose HPV vaccine in Tanzania

  6/2/2020

  Is a single dose of a human papillomavirus (HPV) vaccine sufficient to induce an immune response capable of preventing HPV infection and cervical cancer? That is an area of focus of the Frederick National Laboratory’s HPV Serology Laboratory, this time with a new collaboration with the London School of Hygiene & Tropical Medicine School to investigate immune responses to a single dose of the HPV vaccine in girls in Tanzania.  

• FNL supports website development for official COVID-19 treatment guidelines

  5/29/2020

  FNL supports website development for official COVID-19 treatment guidelines

• Ebola clinical trial supported by FNL receives “Trial of the Year” award

  5/27/2020

  The Pamoja Tulinde Maisha (PALM, Kiswahili for “together save lives”) trial, a large Ebola research effort supported by the Frederick National Laboratory, has received the David Sackett Trial of the Year Award for 2019.

• Study on “rapid autopsy” tumor tissue as a valuable research tool is among abstracts presented at 2020 ASCO Virtual Scientific Program

  5/26/2020

  Tissue obtained from tumors during an autopsy conducted shortly after a cancer patient’s death provides unique insights into how the tumors evolved, spread and resisted treatment. The Frederick National Laboratory’s Molecular Characterization Laboratory reports on results of a study on preclinical models established from “rapid autopsy” tumors during the 2020 American Society for Clinical Oncology Virtual Scientific Program, May 29-31.

• 

  Biopharma Update on the Novel Coronavirus: May 22

  5/22/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.